NIPH Clinical Trials Search

JRCT ID: jRCT1050210193

Registered date:14/03/2022

Study on the effect of the original exercise program on muscle strength, muscle mass, and metabolic parameters

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedType2 diabetes
Date of first enrollment14/03/2022
Target sample size50
Countries of recruitment
Study typeInterventional
Intervention(s)Participating patients perform the exercise therapy program (aerobic and resistance exercise), as follows. Aerobic exercise: 3-5 days or more per week (without 2 days interval), totaly more than 10 kcal/kg/week (equivalent to 4METs x 2.5 hours). Resistance exercise: consisted of core-menus (trunk and lower limb training) and sub-menus (upper limb and chest training) which are set to low, medium, and high intensity, 2 to 3 days per week (non-consecutive days).


Primary OutcomePlasma hypoxanthine (HX), xanthine (Xan), uric acid (UA), and xanthine oxidoreductase (XOR) activity before and after WBV exercise Body composition evaluated by In Body, grip strength,lower limb extension, and thigh circumference
Secondary OutcomeInternational Physical Activity Questionnaires(IPAQ) Eating behavior questionnaire Food preference questionnaire Exercise function test such as chair-stand test and 6-minute walking distance

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 74age old
Include criteriaType 2 diabetic patients admitted to the Department of Diabetes, Endocrinology, and Metabolism, Osaka University Hospital (regardless of gender), who meet the following criteria 1) Patients aged 20 to 74 years 2) Patients diagnosed with type 2 diabetes by the doctors 3) Patients who have agreed to participate in the program
Exclude criteria1) Patients with type 1 diabetes or secondary diabetes 2) Fasting plasma glucose; 250mg/dl or more 3) Resting blood pressure; 180/110mmHg or more 4) Diabetic nephropathy with stage 3 or more (urinary albumin/creatinine ratio; 300 mg/g Cr or more or persistent proteinuria) 5) Severe neuropathy (sensory and autonomic neuropathy) 6) Unstable diabetic retinopathy such as preproliferative or proliferative retinopathy 7) Unstable macroangiopathy such as cardiovascular disease and peripheral arterial disease 8) Severe liver damage (decompensated cirrhosis, etc.) 9) Heart failure (NYHA; II or more or patients on limited physical activity) 10) Patients at high risk of hypoglycemia 11) Patients whose condition is thought to worsen by whole body vibration (e.g. dizziness, etc.) 12) Patients who are at risk of falling and are judged to have difficulty in performing whole body vibration 13) Female patients who are pregnant or potentially pregnant and are lactating 14) Patients who are judged by the doctors to be inappropriate for participation in the program due to complications (e.g. blindness, decreased ADL, scheduled surgery, uncontrollable active infections, etc.) 15) Patients who are difficult for the doctors to assess the effectiveness of the program (e.g. complications of psychiatric disorders or mental disorders, having difficulty in communicating with medical staff, alcohol-dependent / drug-dependent, planning a long trip during the program, opposed by their families, and a rapid weight loss more than 4.5 kg within 3 months, etc.) 16) Patients that the primary investigator or the doctors consider to be inappropriate for other reasons

Related Information


Public contact
Name Yusuke Kawachi
Address 2-2, Yamada-oka, Suita, Osaka, Japan Osaka Japan 565-0871
Telephone +81-6-6879-3737
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University
Scientific contact
Name Hitoshi Nishizawa
Address 2-2, Yamada-oka, Suita, Osaka, Japan Osaka Japan 565-0871
Telephone +81-6-6879-3732
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University